<DOC>
	<DOCNO>NCT00980382</DOCNO>
	<brief_summary>This study open-label , single center , nonrandomized study , consist dose-escalating phase I study advanced solid cancer subsequent phase II study metastatic gastric cancer . In phase I study , aim determine MTD recommend dose S-1 combine docetaxel give every 3 week . Dose level escalate schedule following - S-1 ( level 0 , 1/2 , 3/4 , 5 : 60 , 70 , 80 , 90 mg/m2/day ) q 12 hour po Days 1-14 ) - Docetaxel ( level 0/1,2/3 , 4/5 : 25 , 30 , 35 mg/m2 ) mix d5w 200 ml iv 60 min : Days 1 , 8with dexamethasone 8 mg po q 12hr 3 day ( total 6 dos : D0-2 ) parenteral pheniramine maleate 1 ample ( 45.5mg ) docetaxel</brief_summary>
	<brief_title>A Phase I/II Study S-1 Weekly Docetaxel Metastatic Gastric Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . In phase I : histologically cytologically confirm advanced solid Cancer In phase II : histologically cytologically confirm metastatic gastric adenocarcinoma 2 . Age : 18 year 3 . No prior chemotherapy radiotherapy ( include adjuvant hemotherapy ) phase II portion Previous chemotherapy two regimen ( include adjuvant chemotherapy ) allow phase I portion ; patient require discontinued chemotherapy , immunotherapy , radiotherapy least 4 week entry phase I portion 4 . Disease status must measurable disease define : Lesions accurately measure least one dimension &gt; 10 mm spiral CTscan palpable LN ( include supraclavicular LN ) physical examination . 5 . Performance status : ECOG 02 6 . Adequate major organ function include follow Hematopoietic function : WBC &gt; 4,000/mm3 ANC &gt; 2,000/mm3 , Platelet count Â³ 100,000/mm3Hepatic function : Bilirubin UNL ( Upper normal limit ) , AST/ALT level 2.5X UNL Renal function : Creatinine UNL 7 . Patients sign inform consent 1 . Inadequate cardiovascular function : New York Heart Association class III IV heart disease Active angina myocardial infarction within past 6 monthsHistory significant ventricular arrhythmia require medication antiarrhythmic significantconduction system abnormality 2 . Other malignancy within past 3 year except nonmelanomatous skin cancer carcinoma situ cervix 3 . Pregnant nursing woman 4 . Serious concurrent infection nonmalignant illness uncontrolled whose control may jeopardize complication study therapy 5 . Psychiatric disorder would preclude compliance 6 . Patients receive concomitant treatment drug interact S1 docetaxel : flucytosine , phenitoin , warfarin et al .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Stomach Neoplasms</keyword>
	<keyword>phase I/II</keyword>
	<keyword>Combination chemotherapy</keyword>
	<keyword>S-1</keyword>
	<keyword>Docetaxel</keyword>
</DOC>